Polfarmex and dried flower: what the register confirms and what it does not contain

Who is Polfarmex and where does its dried flower come from?

Polfarmex is a Polish pharmaceutical company from Kutno, operating since 1989, for which dried flower is a marginal part of its offer. The company is responsible for one entry in the national register of pharmaceutical raw materials that includes hemp flowers. The source of the raw material is not disclosed in the public register, as there is no section for the manufacturer.

The company was established in 1989 under the name Polfa-Farmex and started with the trade of medications and imported raw materials. The facility in Kutno began construction in 1994, at which time the current name was adopted, and in 1999 the entity was transformed into a joint-stock company. Today's offer includes prescription medications, over-the-counter products, dietary supplements, and cosmetics, employing around six hundred thirty people. The company’s timeline on its website runs from 1989 to the relocation of the biotechnology laboratory in 2023 and does not mention hemp even once.

The role that this company plays regarding dried flower is explicitly named in the document: responsible entity. The permit number 30075 is valid until September 7, 2027, and since such permits are generally issued for five years, the decision was most likely made in the fall of 2022, which aligns with the registration year reported by industry press. The issuance date is not stated in the register. Being a responsible entity does not imply cultivation or processing. Domestic cultivation of hemp for pharmaceutical raw material became legally possible in 2022, but the first Polish harvest is not expected until 2027, so the dried flower currently available in pharmacies comes from imports. There is no trace of a private plantation in the company’s materials.

Which strains from Polfarmex reach Polish pharmacies?

One. The pharmacy inventory of this service associates only Pink Kush with Polfarmex, a strain characterized by a profile driven by nerolidol. However, the same trade name is associated with four other responsible entities, so the label with the strain does not yet indicate whose dried flower the patient will receive at the pharmacy.

The register of pharmaceutical raw materials does not recognize strain names. Of the 56 entries with hemp flowers, only one carries the designation of cultivar in its name, and its permit expired in 2023. The rest, including the entry for the company described here, is described solely by the declared content of ingredients. Thus, the assignment of a strain to an entry comes from pharmacy catalogs and sales descriptions, not from a decision by the office. The registered name carries a declared value, so we quote it without this component, and the value itself is described separately as a range.

The relevance of such a compilation is fragile. The permit expires after five years, the entity can withdraw the entry from circulation without announcement, and the pharmacy orders what the wholesaler currently has. We maintain the current state separately, in the compilation of available strains, and there the changes in the assortment occur. Store category drought includes products available over the counter and does not correspond with the pharmaceutical raw material described here. The terpene profile, lineage, and pharmaceutical versions of this strain are discussed in a separate entry about Pink Kush.

What is the difference between the responsible entity and the raw material producer?

The scope of responsibility. The responsible entity is accountable for the product approved for sale and its quality to the authorities, while the producer physically cultivates or processes the plant material. The public list of pharmaceutical raw materials only mentions the former, so the reader has nothing to look for when asking about the origin of the dried flower.

The list has ten columns: ordinal number, name of the item, commonly used name, strength, form, license number, expiration date, responsible entity, packaging, and active substance. At the time of writing, it contains 56 entries with hemp flowers, listed under 20 responsible entities. Canopy Growth has the most entries, while those entities that registered a single dried flower have the least, and Polfarmex belongs to this latter group.

There are no columns for the producer, the country of cultivation, or the strain name in this document. This is not an editorial oversight: the list serves to identify items in circulation, not to describe the supply chain. The consequence for the reader is, however, concrete. Two items with the same declared value, managed by two different entities, may come from one cultivation or from two distant ones, and it is impossible to determine this from the list alone. Those who want to know more must refer to the approval decision or the batch documentation, and neither of these things is published online.

What is the difference between Polfarmex's raw material and that of other entities?

The declared content and nothing more that could be verified in a public document. The license ties the item to one nominal THC value, from which producers are allowed to deviate by one-tenth, so the permissible range is 16.2-19.8%. The rest of the differences are commercial declarations, not official records.

The declared value of this item does not stand out either. The list includes five entries with hemp flower of the same nominal strength: alongside Polfarmeks, these are S-LAB, Tilray, Synoptis Pharma, and Tarchomińskie Zakłady Farmaceutyczne Polfa. Four of them are managed by entities registered in Poland, and one is managed by a Portuguese company.

What truly distinguishes the series is the analysis certificate attached to the batch. It goes to the wholesaler and to the pharmacy, not to the packaging given to the patient, and it contains the results of the content measurement and purity testing. The official list, however, does not mention anything about the drying method, nothing about decontamination, or anything about the composition of oils. When a store writes about careful cultivation or exceptional quality of a batch, it does not refer to any record that could be verified. The separation of these two layers is more important with this raw material than with an ordinary drug because the patient compares store descriptions, not the characteristics of the medicinal product, which are not prepared for raw materials.

Does Polfarmex's dried flower come from the same facility as Tilray and S-LAB?

It is unknown, and no public document clarifies this. The claim of common origin circulates in industry services, but it is based on a relationship, not on a registration record. The list of pharmaceutical raw materials does not mention the producer, so it cannot confirm or refute this thesis.

What is documented is this: both Polish entries of the Tilray brand belong to Tilray Portugal Unipessoal Lda., and the producer states on its own website that its facility in Cantanhede, Portugal, has a good manufacturing practice certificate. The S-LAB entry belongs to a company registered in Poland, while the Polfarmex entry belongs to a joint-stock company from Kutno. The name of the producer does not appear with either of these.

The thesis itself comes from texts on an industry portal from May 2025. The author writes that Tilray is the producer of hemp flowers for several Polish entities, including the company described here, and that its registration is related to Tilray. None of these texts provide a source, and the author note describes him as an employee of the sales department of a competing entity from the same market. This does not mean that the thesis is false. It only means that we have a statement from an interested party, and it should be read as such until someone shows a decision or a contract.

The thesis is supported by the coincidence of dates. Three licenses for hemp flowers of the same nominal strength expire on July 1, July 28, and September 7, 2027, so they were issued within ten weeks in the summer of 2022. However, the coincidence of the calendar is not proof of common cultivation.

What is known, and what is not known about Polfarmex's raw material?

What is known is as much as fits in the column of the list: license number, expiration date, form, package size, and name of the active substance. It is unknown who cultivated the plant, what its essential oil composition is, and whether subsequent batches come from the same cultivation. The company itself does not publish anything on this topic.

On the documentation side, there is an analysis certificate for each batch. It is this, not the description in the catalog, that states how much was actually measured in a given package. The declarations of items under which the same strain is issued in Polish pharmacies cover a range of 16.2-24.2% THC, as they consist of separate registration entries from several entities, not the range of one of them.

On the marketing material side, there is everything that stores and portals write about this dried flower: description of aroma, assigned effects, suggested indications. The described company does not endorse these contents itself. Its website lists prescription medications, over-the-counter preparations, supplements, and cosmetics, and there is not a word about hemp on it, even in the company timeline leading up to 2023. An entity that says nothing about the product also leaves nothing to verify, and patient reports circulating on forums describe experiences with a specific package, not the entire registration.

What adverse effects have been reported from Polfarmex's raw material?

None that could be attributed specifically to this entity. Public compilations do not separate reports by registration entries, and with hemp dried flower, they do not even separate them by producers. This does not mean that there were no reports. It only means that no one publishes them in such detail.

The reason is systemic. A response from the Deputy Minister of Health cited in March 2025 states that the pharmaceutical raw material with hemp flowers is not subject to direct supervision by the President of the Registration Office, and the entities conducting its trade are not required to report to the Integrated Monitoring System for Medicinal Products. Supervision over imports operates quantitatively. The report is assigned to a prescription drug with a specific batch number, not to the name of the entity appearing on the packaging.

Reports of adverse effects are collected for medicinal products with a batch number, not for the strain name, so the following pertains to hemp dried flower as a group of raw materials. The most frequently reported symptoms are dry mouth, red eyes, and increased heart rate. Dizziness upon rapid standing, daytime drowsiness, and temporary worsening of short-term memory are less frequently described, as well as anxiety that increases with dosage. A separate issue is medications taken concurrently, especially sedatives and those affecting coagulation: their assessment requires knowledge of the entire list of preparations, not just the description of the plant. We do not provide the frequency of these symptoms numerically, as public compilations for hemp dried flower in Poland do not separate them by individual products.

Frequently asked questions about Polfarmex's hemp dried flower

Does Polfarmex cultivate hemp in Poland?

There is no indication of that. The list of pharmaceutical raw materials mentions the company solely as the entity responsible for the product approved for circulation, and there are simply no columns for the manufacturer or the country of cultivation in this list. The company's own materials do not mention hemp.

How many strains of Polfarmex are available in Polish pharmacies?

One registration entry, associated in pharmacy catalogs with the Pink Kush strain. We maintain current availability in a separate listing, as the product can disappear from circulation without notice and return after a few months.

Is Polfarmex's dried flower the same as that from Tilray?

It is unknown. The claim about a common manufacturer comes from industry journalism without a cited source, and the public list does not contain data that would allow verification in either direction.

Until when is the permit for Polfarmex's dried flower valid?

Until September 7, 2027, according to the list of pharmaceutical raw materials. Permits for pharmaceutical raw materials are issued for five years, so after this date, the product will either be extended or disappear from circulation.

Why do we not provide a single number describing the potency of this dried flower?

Because the declared value has a ten percent tolerance, and a single number would suggest an accuracy that does not exist. For Polfarmex's product, the acceptable range is 16.2-19.8% THC, and this describes what can realistically end up in the packaging.

Where can I find the terpene profile of the strain issued under this product?

In a separate entry about Pink Kush, because the profile describes the strain, not the responsible entity. The list of pharmaceutical raw materials does not contain the profile of any product, so the composition data always comes from outside the official document.

Hemp dried flower is a pharmaceutical raw material issued by a doctor's prescription in the Rpw category, and advertising for prescription medicinal products directed to the public remains prohibited. The material is informational and does not replace a conversation with the attending physician. The editorial text was prepared by the editorial team. ubucha.pl.